Circulating levels of copeptin, a novel biomarker in pre‐eclampsia

Zülfikaroğlu, Ebru; Islimye, Mine; Tonguç, Esra; Payasli, Ahmet; İşman, Ferruh Kemal; Var, Turgut; Danışman, Nuri

doi:10.1111/j.1447-0756.2010.01498.x

Cited by 57 publications

(31 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Copeptin and CTproET-1 did not contribute any added value in our model. So far, copeptin was investigated in just one study with PE and copeptin levels were found to increase markedly in parallel with the severity of PE when compared to women with normal, ongoing pregnancies of similar GAs in the third trimester [20] . In our study copeptin levels were also higher in the preeclamptic group (1.5-fold) but PE was not an independent determinant of higher copeptin in multivariable regression analysis.…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular Biomarkers in Preeclampsia at Triage

Wellmann

Benzing

Fleischlin³

et al. 2014

Fetal Diagn Ther

View full text Add to dashboard Cite

Introduction: To investigate the ability of cardiovascular plasma biomarkers to identify imminent preeclampsia (PE) among pregnant women at triage. Material and Methods: C-terminal pro-arginine vasopressin (copeptin), C-terminal pro-endothelin-1 (CT-proET-1), mid-regional pro-adrenomedullin (MR-proADM), and mid-regional pro-atrial natriuretic peptide (MR-proANP) were prospectively measured in pregnant women presenting at the obstetrical triage units of the University Hospitals of Basel and Zurich, Switzerland. Logistic regression and receiver operating characteristics (ROC) analysis was used to assess and quantify the predictive ability of cardiovascular biomarkers. Results: Of the 147 included women, 27 (18.4%) were diagnosed at admission with PE. All biomarker levels were significantly higher in participants with PE as compared to controls. However, only MR-proANP, MR-proADM and CT-proET-1 were significant and independent predictors of PE, after taking into account the effect of various clinical confounders. The area under the ROC curve (AUC) was 0.62 (95% confidence interval 0.50-0.73) for copeptin, 0.64 (0.52-0.76) for MR-proADM, 0.71 (0.61-0.82) for CT-proET-1, and 0.83 (0.73-0.92) for MR-proANP. The combination of MR-proANP and MR-proADM resulted in the highest diagnostic performance (AUC 0.88; 0.79-0.96). Discussion: Assessment of the cardiovascular plasma biomarkers MR-proANP and MR-proADM holds promise to support diagnosis of PE at triage.

show abstract

Section: Discussionmentioning

confidence: 99%

Cardiovascular Biomarkers in Preeclampsia at Triage

Wellmann

Benzing

Fleischlin³

et al. 2014

Fetal Diagn Ther

View full text Add to dashboard Cite

show abstract

“…However the study did not provide information regarding gestational age of copeptin measurement. This was the first study to elucidate role of copeptin in PE pathogenesis and presented maternal serum level of copeptin as a marker for PE[53]. In another study assessing effect ofvaginal delivery versus caesarean delivery on maternal serum copeptin levels in pregnant women, Foda et al demonstrated increased copeptin levels in PE women compared to normotensive pregnant women.…”

mentioning

confidence: 90%

Promising prognostic markers of Preeclampsia: New avenues in waiting

Jadli

Sharma

Damania

et al. 2015

Thrombosis Research

View full text Add to dashboard Cite

“…Another 10 blood experimental biomarkers (AT-1AA [31], calcyclin, copeptin [34], galectin-1 [36], Gas6 [37], HIF-1aOH [38], IGFALS [41], mammalian HtrA3 [45], NT-proBNP [47], and PTX3 [49]), and four urine ones (C5b-9 [33], nephrin [46], iodine [42], and prolactin [52]) had limited clinical evaluation information, which impeded the evaluation of their performance for the diagnosis of PE. No clinical data were found for the remaining nine blood markers, which consisted of adipsin, α enolase, ADMA, Ba, 2,3-BPGM, Fetal DNA, marinobufagenin, plasma UA [51], and soluble CD117.…”

Section: Resultsmentioning

confidence: 99%

Towards biomarker-based tests that can facilitate decisions about prevention and management of preeclampsia in low-resource settings

Acestor

Goett

Lee

et al. 2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Abstract:In recent years, an increasing amount of literature is emerging on candidate urine and blood-based biomarkers associated with incidence and severity of preeclampsia (PE) in pregnant women. While enthusiasm on the usefulness of several of these markers in predicting PE is evolving, essentially all work so far has focused on the needs of high-resource settings and high-income countries, resulting primarily in multi-parameter laboratory assays based on proteomic and metabolomics analysis techniques. These highly complex methods, however, require laboratory capabilities that are rarely available or affordable in low-resource settings (LRS). The importance of quantifying maternal and perinatal risks and identifying which pregnancies can be safely prolonged is also much greater in LRS, where intensive care facilities that can rapidly respond to PE-related health threats for women and infants are limited. For these reasons, simple, low cost, sensitive, and specific point-of-care (POC) tests are needed that can be performed by antenatal health care providers in LRS and that can facilitate decisions about detection and management of PE. Our study aims to provide a comprehensive systematic review of current and emerging blood and urine biomarkers for PE, not only on the basis of their clinical performance, but also of their suitability to be used in LRS-compatible test formats, such as lateral flow and other variants of POC rapid assays.

show abstract

Circulating levels of copeptin, a novel biomarker in pre‐eclampsia

Abstract: These results suggest that increased maternal levels of copeptin may be involved in the pathogenesis of pre-eclampsia and it may be useful in the assessment of the severity of the disease.

Cited by 57 publications

References 20 publications

Cardiovascular Biomarkers in Preeclampsia at Triage

Cardiovascular Biomarkers in Preeclampsia at Triage

Promising prognostic markers of Preeclampsia: New avenues in waiting

Towards biomarker-based tests that can facilitate decisions about prevention and management of preeclampsia in low-resource settings

Contact Info

Product

Resources

About